HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Andrew B. Becker, MD, PhD

Andrew B. Becker, MD, PhD

Clinical Advisory Board Member

Dr. Becker is President and Founder of Becker Pharmaceutical Consulting, a market research, competitive intelligence and strategic planning consulting firm that provides analytic and strategy services to companies ranging from small biotechnology and medical device companies up to large multinational pharmaceutical companies on a global basis. Dr. Becker received both his medical degree and PhD in Molecular Pharmacology from Stanford University. At Stanford, Dr. Becker’s research focused on signaling pathways for the insulin and IGF–1 receptors, deciphering the structure and function of the insulin degrading enzyme and its role in insulin processing.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes May 7
  • Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma May 6
  • Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting Apr 29
Designed and Secured by Barsec
Copyright ©2025 all rights reserved.
Home - Privacy Policy - Terms of Use